Migraine headaches affect thousands of Americans and millions worldwide. There are several medications that are being prescribed for migraines and for many these do not work well. In a couple of ...

Erenumab, a monoclonal antibody, was approved by the FDA in 2018 and is administered monthly via self-injection of a 70- or 140-mg dose. The treatment blocks the calcitonin gene-related peptide ...

In a review, researchers outlined the safety and efficacy of erenumab, the only monoclonal antibody built to interact with the calcitonin gene related peptide (CGRP) receptor rather than the CGRP ...

Safety profile similar to other trials, with 6 in 10 sustaining medication overuse headache remission over 6 months. HealthDay News — Monthly use of erenumab injections (140mg) is safe and effective ...

SAN FRANCISCO — The fully humanized monoclonal antibody erenumab (Aimovig, Novartis/Amgen) is safe and effective in preventing refractory episodic migraine, new research suggests. Results of a ...

A 52-week open label extension of a previous 12-week double-blind treatment study showed sustained efficacy and safety of erenumab for the treatment of chronic migraine. Perspective from Katherine S.

The first drug of a new drug class can reduce the number of headache days if other prophylactic medications have failed or have not been an option. Erenumab was the first drug of a new drug class for ...

Erenumab was not effective in reducing pain intensity in patients with trigeminal neuralgia, researchers reported in Lancet Neurology. Trigeminal neuralgia is a severe facial pain disorder that is ...

The experimental drug erenumab (AMG 334, Amgen and Novartis) is effective and safe in patients with episodic migraine in whom previous treatments have failed, results of a new phase 3b trial have ...

About The Study: In this study, monthly, 140 mg erenumab injections safely and effectively achieved medication overuse headaches remission in patients with nonopioid chronic migraine and medication ...

Erenumab was the first drug of a new drug class for the prophylaxis of migraine to enter the German market in November 2018. In an early benefit assessment, the German Institute for Quality and ...